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A reduction of either blood pressure or glycemia decreases
some microvascular complications of type 2 diabetes, and we
studied here their combined effects. In total, 4733 older
adults with established type 2 diabetes and hypertension
were randomly assigned to intensive (systolic blood pressure
less than 120mmHg) or standard (systolic blood pressure
less than 140mmHg) blood pressure control, and separately
to intensive (HbA1c less than 0.060) or standard (HbA1c
0.070–0.079) glycemic control. Prespecified microvascular
outcomes were a composite of renal failure and retinopathy
and nine single outcomes. Proportional hazard regression
models were used without correction for type I error due to
multiple tests. During a mean follow-up of 4.7 years, the
primary outcome occurred in 11.4% of intensive and 10.9%
of standard blood pressure patients (hazard ratio 1.08), and
in 11.1% of intensive and 11.2% of standard glycemia control
patients. Intensive blood pressure control only reduced the
incidence of microalbuminuria (hazard ratio 0.84), and
intensive glycemic control reduced the incidence of
macroalbuminuria and a few other microvascular outcomes.
There was no interaction between blood pressure and
glycemic control, and neither treatment prevented renal
failure. Thus, in older patients with established type 2
diabetes and hypertension, intensive blood pressure control
improved only 1 of 10 prespecified microvascular outcomes.
None of the outcomes were significantly reduced by
simultaneous intensive treatment of glycemia and blood
pressure, signifying the lack of an additional beneficial effect
from combined treatment.
Kidney International (2012) 81, 586–594; doi:10.1038/ki.2011.415;
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Both glucose1–5 and blood pressure (BP) lowering6–8 reduce
the risk of several microvascular complications of type 2
diabetes mellitus (T2DM), and epidemiological analyses
suggest that the combined effects of BP and glucose control
may be greater than the benefit of either intervention
alone.9,10 Two large clinical trials provide additional insight
on the combined effects of BP and glycemic control. Intensive
glycemic control significantly reduced microvascular compli-
cations in the UK Prospective Diabetes Study (UKPDS).1,2 A
subset of UKPDS participants with uncontrolled hyper-
tension were randomized to intensive vs. standard BP
control. Participants in the intensive arm achieved a BP
of 144/82 mm Hg and experienced a 34% reduction in
progression of retinopathy, a 29% reduction in onset of
microalbuminuria (450 mg/l), and a 37% reduction in a
composite measure of microvascular end points; however,
there was no reduction in development of macroalbuminuria
(4300 mg/l) or renal failure (RF).8 These investigators also
reported that the incidence of ‘any diabetes-related end point’
was lowest in those in both the intensive BP and intensive
glycemia arms of the trial.11
The ADVANCE trial used a double-blind factorial design
to assess the effect of BP and glycemic control on cardio-
vascular and microvascular outcomes in patients with
T2DM.6 The impact on microvascular complications of
intensive BP control alone,6 intensive glycemic control
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alone,3 and their combined effect has been reported.12 Rates
for all renal events and for new onset of microalbuminuria
were reduced by intensive BP control, intensive glycemic
control, and both, with participants randomized to both
intensive arms having the lowest hazard ratio (HR). How-
ever, the effect of each treatment was not significantly altered
by the other. In aggregate, these data suggest a possible
additive benefit of BP and glycemic control on prevention
or progression of certain microvascular complications,
particularly those related to microalbuminuria and macro-
albuminuria.
The ACCORD-BP trial13 reported that participants random-
ized to a systolic BP (SBP)o120 mm Hg (achieved mean SBP
119.3 mm Hg) vs.o140 mm Hg (achieved mean 133.5 mm Hg)
had no significant effect on the composite cardiovascular end
point or its components, and did not reduce the progression of
retinopathy; however, a detailed analysis of microvascular
outcomes of this trial has not been reported. Intensive BP
control did lead to a 16% reduction of incident microalbumin-
uria, but not macroalbuminuria. Analysis of microvascular
outcomes in the main ACCORD glycemia trial showed that
intensive glycemic control did not affect a prespecified
composite measure of advanced microvascular complications,
including RF and retinopathy requiring photocoagulation
and/or vitrectomy.4 However, intensive glycemic control
significantly improved two of five secondary measures of
nephropathy (microalbuminuria and macroalbuminuria),
whereas one measure deteriorated with intensive glucose
control.4 In addition, the incidence of one measure of
diabetic eye disease and three measures of neuropathy were
reduced with intensive glycemic control. In a substudy of
ACCORD, intensive glucose control slowed progression of
retinopathy, but intensive BP control resulted in no beneficial
effect on retinopathy, with a nonsignificant worsening of
moderate visual loss with intensive BP control.14
The present analysis of the ACCORD-BP trial has two
aims as follows: (1) to report the results of intensive vs.
standard BP control on 10 predefined microvascular out-
comes and to examine the combined effects of intensive BP
and glycemic control on these outcomes, and (2) to assess
potential benefits of intensive BP and glycemic control on
development and progression of microalbuminuria and
macroalbuminuria, and on the development of RF.
RESULTS
Table 1 summarizes the 10 predefined ACCORD micro-
vascular outcomes and their frequencies of assessment.
Baseline characteristics of participants stratified by the four
intervention groups are shown in Table 2. Changes in BP and
glycemic control occurred during the trial, as previously
described4,13 (see Supplementary Table S1 online). In
addition, minor but significant differences in serum trigly-
cerides, high-density lipoprotein cholesterol, serum creati-
nine, and body mass index were observed between the
intervention arms (Supplementary Table S1 online). The
present analysis did not adjust for parameters measured
during the post-randomization study period.
Results of BP treatment arm assignment are shown in
(Figure 1a). Over a mean follow-up period of 4.7 years, the
primary microvascular outcome occurred in 527 of 4726
participants, including 11.4% in the intensive BP arm and
10.9% in the standard BP arm (HR¼ 1.08, 95% confidence
interval (CI): 0.91–1.28). Intensive BP control reduced the
development of microalbuminuria (HR¼ 0.84, 95% CI:
0.72–0.97, P-value¼ 0.019), but the effect on incident
macroalbuminuria was not significant (HR¼ 0.81, 95% CI:
0.63–1.03, P-value¼ 0.087). No effects of intensive BP control
were observed on any of the other microvascular outcomes
(Figure 1a). Intensive vs. standard glycemic control in
participants in the ACCORD-BP trial reduced three of the
microvascular outcomes but not the primary composite
outcome for advanced microvascular disease (Figure 1b).
However, there was no interaction between intensive BP and
intensive glycemic control.
Table 1 | Definition of ACCORD microvascular outcomes and their frequency of assessment
Outcome category Label Definition
Assessment
frequency
Primary composite Primary Development of renal failure (initiation of dialysis or ESRD, renal transplantation, or serum
creatinine 4292mmol/l) or retinal photocoagulation or vitrectomy to treat retinopathy
Every 4 months
Nephropathy Neph-1 Development of incident microalbuminuria (defined as urine albumin/creatinine ratio
X3.39mg albumin/mmol creatinine and o33.9mg albumin/mmol creatinine)
Annually
Neph-2 Development of incident macroalbuminuria (defined as urine albumin/creatinine ratio
X33.9mg albumin/mmol creatinine)
Annually
Neph-3 Development of renal failure (defined as initiation of dialysis or ESRD, or renal transplantation,
or serum creatinine 4292mmol/l in absence of an acute reversible cause)
Every 4 months
Diabetic eye
complications
Eye-1 Retinal photocoagulation or vitrectomy to treat retinopathy Annually
Eye-2 Eye surgery for cataract extraction Annually
Eye-3 Three-line decrease in visual acuity (as measured using Log MAR visual acuity chart) Biennially
Neuropathy Neuro-1 Score of 42.0 on the Michigan Neuropathy Screening Instrument (MNSI) Annually
Neuro-2 Loss of vibratory sensation (tested using 128Hz tuning fork) Annually
Neuro-3 Loss of light touch (as measured by 10 g force monofilament test) Annually
Abbreviation: ESRD, end-stage renal disease.
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Analyses of possible two-way interactions are provided
in Supplementary Tables S2 and S3. In participants assigned
to intensive BP control (Supplementary Table S2 online),
intensive glycemic treatment reduced the incidence of macro-
albuminuria compared with standard glycemic control
(HR¼ 0.58, P-value¼ 0.004); however, there was no signi-
ficant interaction. In participants assigned to intensive glyce-
mic control (Supplementary Table S3 online), intensive BP
control resulted in a reduction in incident microalbumin-
uria compared with standard BP control (HR¼ 0.76,
Intensive
Outcome
Primary
% N % N
11.4 2356 10.9 2370
150125.0147320.8
5.7
2.6 2356 2.7 2370 1.00 (0.71,1.43)
2038 7.1 2058 0.81 (0.63,1.03)
1.08 (0.91,1.28)
0.84 (0.72,0.97)Neph-1
P -value
0.409 0.717
0.019 0.220
0.087 0.241
0.991 0.826
0.5590.371
0.816 0.145
0.5260.728
0.311
0.105
0.282 0.352
0.901
0.963
Interact P -value
P-value
0.969 0.717
0.2200.218
0.002 0.241
0.8260.562
0.691 0.559
0.1450.168
0.119
0.098 0.901
0.9630.022
0.001 0.352
0.526
Interact P -value
Neph-2
Neph-3
Eye-1
Eye-2
Eye-3
Neuro-1
Neuro-2
Neuro-3
Outcome % %N N
236011.2236611.1
22.2
5.3
2.7
9.2
14.7
34.3
53.6 1389 56.2 1352
157446.9157742.4
11.5 2130 14.9 2119
0.50 0.75
Intensive better Standard better
1.00 1.50
0.76 (0.64,0.89)
0.92 (0.83,1.02)
0.89 (0.80,0.98)
2346 36.8 2345 0.93 (0.84,1.02)
2268 16.1 2276 0.90 (0.78,1.05)
2268 9.5 2276 0.96 (0.80,1.16)
2366 2.5 2360 1.11 (0.78,1.58)
2043 7.6 2053 0.68 (053,0.87)
1512 23.7 1462 0.91 (0.78,1.06)
HR (95% CI)
1.00 (0.85,1.19)Primary
Neph-1
Neph-2
Neph-3
Eye-1
Eye-2
Eye-3
Neuro-1
Neuro-2
Neuro-3
12.5 2134 13.9 2115 0.91 (0.77,1.08)
Intensive better Standard better
0.50 0.75 1.00
0.92 (0.83,1.02)
1.50
158246.6156942.6
53.4 1353 56.3 1388 0.95 (0.86,1.05)
0.98 (0.89,108)235236.1233935.0
15.0 2262 15.8 2282 0.98 (0.85,1.14)
1.09 (0.90,1.32)22829.122629.6
Standard
Intensive Standard
HR (95% CI)
Figure 1 | Effect of intensive versus standard blood pressure (BP) and glycemic control on microvascular outcomes. Forest plot
depicting effects of randomized blood pressure (a) and glycemia (b) treatments on selected microvascular events with P-values for tests of
two-way interactions between treatments (‘Interact P-value’ column).
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P-value¼ 0.013) and resulted in a near-significant reduction
in the risk of macroalbuminuria (HR¼ 0.68, P-value¼
0.052), again without a significant interaction. Potential two-
way interactions between BP and glycemia treatment arm
assignments and baseline history of clinical cardiovascular
disease were also determined for each outcome and are
summarized in Supplementary Tables S4 and S5; interactions
were not significant for any of the outcomes.
Relationships between BP and glycemia interventions and
development of macroalbuminuria were explored after strati-
fying by baseline microalbuminuria status (Table 3). In
participants with no microalbuminuria at baseline, intensive
BP control was not associated with a reduction in inci-
dent macroalbuminuria (HR¼ 1.14, 95% CI: 0.66–1.96). In
contrast, among participants with microalbuminuria at base-
line, intensive BP treatment was associated with reduced inci-
dence of macroalbuminuria (HR¼ 0.71, 95% CI: 0.54–0.93).
However, the interaction test for differential treatment
effects across the strata of baseline microalbuminuria was
not significant (interaction P-value¼ 0.134); thus, the pooled
estimate of the HR for BP treatment (HR¼ 0.84, 95% CI:
0.63–1.03, P-value¼ 0.09; Figure 1a and b) remained the
more appropriate relative risk measure. Assignment to
intensive glycemic control was associated with a reduc-
tion in incident macroalbuminuria among participants
without microalbuminuria at baseline (HR¼ 0.55, 95% CI:
0.32–0.97), and to a lesser extent among participants with
microalbuminuria at baseline (HR¼ 0.77, 95% CI: 0.59–1.01;
Table 3). Again, the test for interaction between glycemic
control and baseline microalbuminuria was not significant
(P-value¼ 0.2997); hence, the pooled estimate is more
appropriate (HR¼ 0.68, 95% CI: 0.53–0.87, P-value¼ 0.002;
Figure 1a and b).
Renal failure developed in 124 (2.6%) of 4726 participants
in the ACCORD-BP trial (Figure 1); 17 exhibited serum
creatinine 4292 mmol/l on a single blood draw, the
remaining 107 initiated dialysis. Among 3182 participants
without microalbuminuria at baseline, 63 (2.0%) developed
RF, whereas 33 of 1216 (2.7%) with microalbuminura at
baseline developed RF, and 26 of 285 participants with
macroalbuminuria at baseline (9.1%) developed RF (two
participants with RF did not have baseline urinalyses). Thus,
approximately half (63/122) of all participants who devel-
oped RF had neither microalbuminuria nor macroalbumi-
nuria at baseline. Figure 2 shows the relationship between
baseline and follow-up albuminuria and subsequent RF
among the 4232 participants who had baseline and at least
one follow-up urine albumin measurement before occurrence
of RF; 74 participants from this group developed RF.
Among 2894 participants with no albuminuria at base-
line, 36 developed RF, and 33 of the 36 never exhibited
albuminuria during the trial. Among 1101 participants with
Table 3 | Effect of randomized treatments on follow-up incident macroalbuminuria, stratified by baseline microalbuminuria
Baseline microalbuminuria Intensive BP arm Standard BP arm HR 95% CI P-value Interaction P-value
No 27/1473 (1.8%) 25/1501 (1.7%) 1.14 0.66–1.96 0.6394 0.1340
Yes 90/565 (15.9%) 122/557 (21.9%) 0.71 0.54–0.93 0.0121
Intensive glycemia arm Standard glycemia arm
No 19/1512 (1.3%) 33/1462 (2.3%) 0.55 0.32–0.97 0.0403 0.2997
Yes 89/531 (16.8%) 123/591 (20.8%) 0.77 0.59–1.01 0.0603
Abbreviations: BP, blood pressure; CI, confidence interval; HR, hazards ratio.
No baseline micro-or
macroalbuminuria
N=2894 (68.4%)
No micro-or
macroalbuminuria
N=2421 (83.7%)
Microalbuminuria
N=429 (14.8%)
Macroalbuminuria
N=44 (1.5%)
RF
N=1 (2.3%)
RF
N=2 (0.5%)
RF
N=33 (1.4%)
Baseline
microalbuminuria
N=1101 (26.0%)
No micro-or
macroalbuminuria
N=379 (34.4%)
Microalbuminuria
N=572 (52.0%)
Macroalbuminuria
N=150 (13.6%)
RF
N=4 (2.7%)
RF
N=17 (3.0%)
RF
N=3 (0.8%)
Baseline
macroalbuminuria
N=237 (5.6%)
No micro-or
macroalbuminuria
N=22 (9.3%)
RF
N=0 (0.0%)
RF
N=2 (2.5%)
RF
N=12 (8.8%)
Macroalbuminuria
N=136 (57.4%)
Microalbuminuria
N=79 (33.3%)
Figure 2 | Follow-up urine albuminuria and renal failure (RF, dialysis or serum creatinine 4292lmol/l) in 4232 ACCORD-BP
Trial participants with at least one follow-up urine albumin measurement before occurrence of RF. Follow-up microalbuminuria
(urine albumin-to-creatinine ratio or UACRX3.39mg albumin/mmol creatinine) and macroalbuminuria (UACRX33.9mg albumin/mmol
creatinine) was determined by urinalysis performed every 2 years. Participants with microalbuminuria or macroalbuminuria at baseline, but
a maximum urine albumin-to-creatinine ratio value o3.39mg/mmol at all subsequent assessments regress to ‘No microalbuminuria or
macroalbuminuria’. Participants with macroalbuminuria at baseline but a maximum urine albumin-to-creatinine ratio valueX3.39mg/mmol
and o33.9mg/mmol at all subsequent assessments regress to ‘Microalbuminuria’. Of 124 participants who experienced RF during the
course of the trial, 2 did not have baseline urinalysis performed, 6 did not have post-randomization urinalysis performed, and 42 had onset
of RF before the first post-randomization urinalysis and are not included in the figure.
590 Kidney International (2012) 81, 586–594
or ig ina l a r t i c l e F Ismail-Beigi et al.: Microvascular outcomes in the ACCORD-BP trial
microalbuminuria at baseline, 22 developed RF, and among
237 participants with macroalbuminuria at baseline 14
developed RF. Less than half (33/74 or 45%) of the
participants without baseline albuminuria who developed
RF did not have albuminuria during the trial, and only 19 of
the 74 participants (26%) who developed RF had prior
macroalbuminuria either at baseline or during the trial.
Table 4 shows results of a proportional hazard regression
model for time to RF during the trial as a function of baseline
renal function variables, BP and glycemia treatment arm
assignments, and history of clinical cardiovascular disease.
Among the baseline variables listed, a higher serum creatinine
(HR¼ 1.64, 95% CI: 1.21–2.23 for every 44.2 mmol/l increase;
Po0.001) and macroalbuminuria (HR¼ 4.42 vs. no albu-
minuria, 95% CI: 2.73–7.14, Po0.0001) were associated with
increased risk of RF during the trial. Baseline microalbumin-
uria (vs. no albuminuria), history of cardiovascular disease,
and inclusion in the intensive or standard glycemia or BP
arms did not predict development of RF.
DISCUSSION
Although the primary aim of the main ACCORD trial was to
study the effect of intensive vs. standard glycemic control on
cardiovascular outcomes, ocular, renal, and neural outcomes
were systematically measured as well.4 In the ACCORD-EYE
study, development or progression of retinopathy was shown
to be reduced by 33% by intensive glycemic control but
not by intensive BP control.14 In addition, as described
previously,4 in the entire ACCORD population of 10,251
participants, intensive glycemic control did not alter the
occurrence of the primary composite microvascular end
point, but reduced the incidence of microalbuminuria by
21% at the end of the 3.5 (mean) years of randomized
treatment and by 15% afterB1.5 years of further follow-up.4
In addition, reductions of several other microvascular end
points (incident macroalbuminuria, cataract surgery,
Michigan Neuropathy Screening Instrument score 42 for
neuropathy, loss of ankle jerk, and loss of pressure sensation)
were evident after 5 years of follow-up.4
Our analysis of microvascular outcomes in 4733 partici-
pants in the ACCORD-BP trial reported here adds to these
prior findings.13 Over a mean follow-up period of 4.7 years,
intensive BP treatment achieved mean SBP of 119.3 mm Hg
in contrast to 133.5 mm Hg with standard treatment. As
previously reported, this intervention led to no significant
effect on the composite cardiovascular end point or its
components,13 nor did it reduce the progression of retino-
pathy in the ACCORD-EYE study.14 In the present analysis,
intensive vs. standard BP control was associated with a 16%
reduction of new microalbuminuria; development of macro-
albuminuria was nominally reduced by 19%, but this effect
fell short of statistical significance, possibly due to the smaller
number of events. The lack of significant association between
intensive BP control and reduction in microvascular
complications was due to small observed effects for some
outcomes and a lack of statistical power for others
(Supplementary Table S6 online); in particular, the study
was clearly underpowered to detect development of incident
macroalbuminuria and overt RF.
The lack of effect of intensive vs. standard BP control on
the composite cardiovascular outcome, use of medications,
and rates of adverse events in the ACCORD-BP study were
reported previously.13 Our finding of relatively modest effects
of maintaining a substantial (B14 mm Hg) reduction in SBP
on microvascular outcomes deserves comment. One possible
explanation is that the patient population studied in the
ACCORD-BP trial had, on average, long duration of diabetes,
and thus a substantial burden of preexisting microvascular
complications. In such a population, the individuals most
vulnerable to developing early complications may have
already done so, and those with more advanced micro-
vascular damage might be unresponsive to further intensi-
fication of treatment because of irreversible structural
changes. Another interpretation suggests that, in this specific
population, additional lowering of BP beyond the level
achieved in the control arm of the trial is not beneficial. The
smaller-than-expected benefit of lower SBP in ACCORD is
similar to that predicted by an epidemiological analysis of the
UKPDS population,15 where 10 mm Hg lower SBP was
associated with only a 13% lower risk of pooled micro-
vascular end points (retinopathy requiring photocoagulation,
vitreous hemorrhage, fatal or non-fatal RF). The UKPDS
investigators raised the possibility that the disparity between
this epidemiological association and the treatment effect
observed in the randomized BP study (37% reduction of
microvascular end points) might have been due to favorable
effects of the antihypertension agents used (mainly captopril
and atenolol) in addition to their effects on lowering BP
alone. In ACCORD, both the standard and intensive BP
treatment strategies used multiple classes of antihypertension
medications, a mean of 2.1 with standard and 3.4 with
Table 4 | Proportional hazards regression model for time
development of renal failure (nephropathy outcome #3;
defined as initiation of dialysis or ESRD, or renal
transplantation, or rise of serum creatinine 4292lmol/l in
absence of an acute reversible cause) including baseline
renal measures as covariates
Parameter HR 95% CI P-value
Baseline serum creatinine
(44mmol/l increase)
1.64 1.21–2.23 0.0014
Baseline urine albuminuria
Microalbuminuria (UAlb:Cr ratio
X3.39mg albumin/mmol
creatinine vs. no albuminuria
1.34 0.88–2.04 o0.0001a
Macroalbuminuria (UAlb:Cr ratio
X33.9mg albumin/mmol
creatinine) vs. no albuminuria
4.42 2.73–7.14
Abbreviations: BP, blood pressure; CI, confidence interval; ESRD, end-stage renal
disease; HR, hazards ratio; Ualb:Cr, urine albumin-to-creatinine ratio.
aTwo degree-of-freedom test.
Model also includes terms for glycemia treatment arm assignment, BP treatment
arm assignment, and baseline history of cardiovascular disease (CVD).
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intensive treatment within 1 year of randomization.13 At the
end of the study, 80% of participants in the standard and
90% in the intensive arm were taking an angiotensin-
converting-enzyme inhibitor or an angiotensin-receptor
blocker, with 56% and 80% on diuretics, and 43% and
61% on beta-blockers, respectively. Thus, the putative
beneficial effects of medications derived from presumed
non-BP-reduction mechanisms may have been less in
ACCORD than in other trials. Further analysis is necessary
to explore the potential effects of medication usage on these
outcomes.
In this analysis, as in the UKPDS and ADVANCE
trials,11,12 no significant interactions were found between
simultaneous intensive BP and glycemic control for micro-
vascular end points. That is, the joint effect of intensive BP
and glycemia interventions were neither synergistic nor
differential in nature, and there were no outcomes for
which both interventions were simultaneously significantly
efficacious. For example, in the intensive glycemia arm of
this study, the incidence of microalbuminuria and macro-
albuminuria appeared to be lower in participants who were
in the intensive compared with the standard BP treatment
arm, suggesting that it might be clinically advantageous to
pursue a joint intensive strategy to prevent these micro-
vascular outcomes. However, the interaction P-value for the
two interventions was not significant, indicating that this
BP effect in the intensive glycemia arm was not significantly
different from the BP effect in the standard glycemia arm.
Moreover, the results observed in the intensive glycemia
treatment arm were not statistically different from those
in the standard glycemia arm. It is remarkable that two
such different interventions targeting dissimilar risk factors
appear to have no significant additive effect on microvascular
outcomes.
Of particular interest in this analysis is the impact on renal
outcomes. Albuminuria is an established risk factor and
surrogate for diabetic kidney disease and RF.16,17 Poor
glycemic control has been associated with microvascular
complications in T2DM,18,19 and results of randomized
controlled trials have shown that intensive control of BP and
glycemia reduces albuminuria.1,3–5 In agreement with these
studies, we also observed a reduction in albuminuria with
intensive BP and glycemic control. However, whether
albuminuria is a frequent predictor for progressive renal
disease in T2DM is less certain. In the UKPDS, only half of
the participants who developed chronic kidney disease
exhibited albuminuria either before or after the onset of
chronic kidney disease, and less than 20% of those with
chronic kidney disease exhibited albuminuria before devel-
oping chronic kidney disease.20 Similar findings have been
reported by other investigators.21 Our present analysis shown
in Figure 2 concurs and shows that 33 out of 74 (45%) of the
participants who developed RF did not have microalbumin-
uria or macroalbuminuria at baseline or during the trial, and
that only about 20% of participants who developed RF had
prior macroalbumiuria. These observations suggest that
microalbuminuria is not a constant marker for the develop-
ment of RF in T2DM.
The lack of a beneficial effect of intensive BP or glycemic
control on incident RF is consistent with findings in the
larger ACCORD trial,4,22 and is similar to results reported by
the VADT and ADVANCE trials.3,5 Potential reasons for this
apparent lack of benefit include (1) small number of events,
(2) a very long duration of exposure to hypertension and
hyperglycemia might be necessary for the development of
RF, (3) the duration and/or the intensity of treatment
was inadequate, and (4) treatments were initiated late in
the course of the disease when pathological changes were
irreversible. In this context, it is worth noting that rates of RF
were not affected by intensive glycemic control in partici-
pants with newly diagnosed T2DM who were enrolled in the
UKPDS and followed up for 10.7 years.1 The nearly equal
percentage of participants who developed RF in the intensive
and standard glycemic and BP treatment arms of all the
above-mentioned studies suggests that the potential bene-
ficial effect of intensive treatment may be small. It should be
acknowledged that in patients with both T2DM and
hypertension, the respective contribution of either condition
to the development of RF is unknown. Finally, a kidney
biopsy study reported that 23% of diabetic patients with 2 g
of albumin excretion per day had nondiabetic causes of
glomerulopathy and had no retinopathy.23 Regardless, the
multifactorial nature and the complex set of mechanisms
underlying the pathogenesis of T2DM suggests that other
factors, in addition to hypertension and hyperglycemia, may
have important roles in the development of RF in this
disease.
This study has several strengths, including the large
sample size, the randomized controlled design, and analysis
according to the intention-to-treat principle. The study has a
number of limitations, including the fact that neither the
investigators nor participants were blinded to treatment arm
assignment; there were few RF events and thus low power to
detect treatment effects for that outcome (although neither
treatment strategy showed a potential of being efficacious);
diagnosis of albuminuria was based on the albumin-
to-creatinine ratio measured on spot-urine samples instead
of timed albumin excretion rate; and the assessment of
multiple outcomes in a single analysis means that the
experiment-wide type I error rate for all outcomes combined
was greater than the nominal 5%. A Bonferroni-type
adjustment applied to 10 outcomes would require signifi-
cance at the 0.005 a-level in order to ensure an experiment-
wide type I error rate of 5%. Only the effect of the glycemica
intervention on development of macroalbuminuria and loss
of pressure sensation met that level of significance.
In summary, the ACCORD-BP trial found that an
intensive strategy achieving mean SBP below 120 mg Hg
reduced new development of microalbuminuria by 16%, but
had no significant effect on other microvascular end points
or composites. No interactions between the glycemic and
BP interventions were found. Furthermore, there were no
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microvascular outcomes for which both BP and glycemia
treatment arm assignment were simultaneously significant;
thus, neither intensive intervention was found to provide
significant further reduction in risk of microvascular out-
comes in the presence of the other. We also note that
albuminuria was not a consistent surrogate marker for the
development of RF. Taken together, we conclude that
although older patients with long duration of T2DM,
hypertension, and high cardiovascular risk may obtain
protection from worsening albuminuria by intensification
of either BP or glycemic control, additional benefit from
simultaneous intensive management was not apparent.
MATERIALS AND METHODS
Design overview, setting and participants, and
randomization and follow-up
Eligibility, consort diagrams, processes of recruitment, randomiza-
tion, and masking for the ACCORD main trail and ACCORD-BP
trial have been described previously.4,13,22,24 Targets of the
ACCORD-BP trial with 4733 participants were SBP o120 mm Hg
vs.o140 mm Hg, and the targets for the glycemia trial were HbA1c
o0.060 vs. 0.070–0.079.13,15 The study was approved by the
Institutional Review Boards. Study investigators were masked to
results of interim analyses but unmasked to individual treatment
group assignment and prescribed therapies.
As part of their glycemic and BP interventions, participants
received instructional materials and behavioral counseling, and were
provided with all prescribed glucose-lowering and antihypertension
medications. Study investigators adjusted therapy based on
randomized assignment and response to therapies. Adverse effects
were carefully monitored both locally and centrally to ensure
participant safety.25
Outcomes
This analysis is restricted to the subgroup of 4733 ACCORD
participants who were enrolled in the ACCORD-BP trial. Surveil-
lance for and measurement of prespecified microvascular outcomes
have been described in detail previously.4 The primary composite
outcome was the first occurrence of advanced kidney or eye disease
as manifested by the development of RF (initiation of dialysis or
end-stage renal disease, renal transplantation, or increase in serum
creatinine 4292mmol/l) or retinal photocoagulation or vitrectomy
to treat retinopathy; this outcome was intended to approximate
the primary microvascular outcome of the UKPDS study.1 The 10
outcomes listed in Table 1 were selected from the original list
of 14 prespecified outcomes based on glycemia treatment effect or
clinical importance.4 Individual components of the microvascular
outcomes reported here were measured or assessed using standard
procedures, as reported,4 and are described in the study Manual of
Procedures; more details can be found in the Supplementary
Information online.
Statistical analysis
Participant characteristics at baseline were calculated by glycemia
and BP intervention group assignments. Descriptive statistics
(medians and inter-quartile ranges) of a subset of continuous
factors related to treatment in each trial were calculated by
glycemia and BP treatment arms; differences in these factors
were assessed using the Wilcoxon signed-rank test (Supplementary
Table S1 online).
Occurrence of microvascular events was determined for each
predefined outcome listed in Table 1. For each participant and
outcome, the observation was censored at the last surveillance time
if no event was discovered. If an event was discovered, an event time
was assigned using the midpoint between the time of event discovery
and the most recent prior surveillance time.26
The effect of treatment arm assignment on time to occurrence
of the first microvascular event of each type was analyzed using
proportional hazards regression models to estimate HRs and
assess statistical significance. Graphical depiction of time to event
was performed using product-limit plots. The primary statistical
test for each outcome was taken from a proportional hazards
regression model, which included BP treatment arm assign-
ment, glycemia treatment arm assignment, and an indicator of
history of clinical cardiovascular disease at baseline. The
ACCORD-BP trial was designed to test the (marginal) effect of
intensive vs. standard BP treatment in diabetics in a background
of intensive vs. standard glycemic control; however, the factorial
design allowed the testing of differential effects of combined
BP and glycemia treatments, which was assessed by examining
the two-way interaction between treatments. Log(-log(survival))
plots revealed that the assumption of proportional hazards was
appropriate.
All analyses were performed by intention-to-treat where
participants were analyzed based on treatment arm assignment
regardless of treatments received or adherence to therapies.
Similarly, the entire follow-up period, which included follow-up
after participants assigned to intensive glycemic management
were transitioned to standard therapy, was used for all models.
All tests of significance were performed at the two-sided 5%
a-level. Because 10 outcomes were examined simultaneously, the
probability of one or more significant findings was approxi-
mately 40%, substantially higher than the nominal 5%. We chose
not to perform a Bonferroni-type adjustment because that would
require significance at the 0.005 a-level in order to ensure an
experiment-wide type I error rate of 5%. Analyses were performed
using the SAS version 9.2 software (SAS Institute, Cary, NC). All
outcomes presented in this manuscript were prespecified in the
study protocol.
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